Drugs / QL1205
last change Apr 2019 re-read 2 minutes ago

QL1205

Developed for
wet macular degeneration
Investigated by
Qilu Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03312283 Dec 2017 → Apr 2019 wet macular degeneration Qilu Pharmaceutical Co., Ltd. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as QL1205 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03312283